ABP-300

N/A

Report date: 2022/03/18 09:50:27

Base Information

Drug NameABP-300
Drug Alias Namehuman neutralizing mAb targeting SARS-CoV-2 spike protein RBD (COVID-19)(Abpro/Mabwell)ABP-300MW-05(Mabwell/Abpro)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCoronavirus spike glycoprotein modulatorsAngiotensin-converting enzyme inhibitors
TargetsCoronavirus spike glycoproteinAngiotensin-converting enzyme
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesMabwell (Shanghai) Bioscience Co LtdAbpro Corp
China Registration ClassN/A

Develop Information

Active CompaniesAbpro Corp
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A